Evaluation of the Effects of HP828-101 Versus Standard of Care in the Management of Partial or Full Thickness Wounds

H

Healthpoint

Status

Completed

Conditions

Diabetic Foot Ulcers
Pressure Ulcers

Treatments

Device: Hydrogel/Hydrocolloid
Device: HP828-101

Study type

Interventional

Funder types

Industry

Identifiers

NCT00971048
828-101-09-013

Details and patient eligibility

About

To compare HP828-101 to standard of care for the management of partial or full thickness wounds

Full description

The primary objective is to compare HP828-101 to standard of care for the management of partial or full thickness wounds, evaluated using the Bates Jensen Wound Assessment Tool (BWAT). The secondary objectives are comparison of the proportion of subjects with wound closure by day 22, comparison of pain assessed using a visual analog scale (VAS), and evaluation of moist wound environment as per the BWAT.

Enrollment

88 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • The informed consent document must be read, signed, and dated by the subject or the subject's legally authorized representative before conducting any study procedures or exams. In addition, the informed consent document must be signed and dated by the individual who consents the subject before conducting Visit 1. A photocopy of the signed informed consent document must be provided to the subject, and the original signed document placed in the subject's chart. For subjects that agree to have their wound photographed for the trial, a photo release consent form must be signed and documented as well.
  • Age 18 years or older, of either sex, and of any race or skin type, provided that their skin color, in the opinion of the Investigator, will not interfere with the study assessments.
  • Females, if of child-bearing potential, have a negative urine pregnancy test and agree to use acceptable contraception during the study. Adequate birth control methods are defined as: hormonal-topical, oral, implantable, or injectable contraceptives; mechanical-spermicide in conjunction with a barrier such as a condom or diaphragm; IUD; or surgical sterilization of partner.
  • Have a partial or full thickness PU on the foot or ankle or DFU of <= 6 months duration and between ≥1.0 and ≤ 12.0 cm² in area.
  • Are willing to make all required study visits.
  • Are willing to follow instructions, in the opinion of the Investigator.
  • Have, within 12 weeks prior to randomization, a serum albumin level ≥ 2.0 g/dL (20 g/L); Alkaline phosphatase, AST, ALT, serum creatinine, and BUN levels < 3 x upper limit of normal; HbA1C ≤ 12%; and Hemoglobin >= 8 g/dL. The most recently obtained value must be evaluated against these criteria. Please refer to Appendix 18.1.5
  • Have arterial supply adequacy confirmed by an Ankle Brachial Index (ABI) >= 0.7 and ≤ 1.1 or if the ABI is > 1.1, either a TcPO2 >= 40 mmHg, as measured on the foot, or great toe pressure ≥ 50 mm/Hg,
  • For ulcers that will require surgical debridement prior to enrollment, the wound must be expected to remain a partial thickness wound after debridement.

Exclusion criteria

  • Have a known hypersensitivity to any of the test articles or their components.
  • Have received therapy with another investigational agent within thirty (30) days of Visit 1.
  • Are pregnant or nursing.
  • Have clinical evidence of bacterial or fungal infection of the wound per visual/clinical assessment.
  • Have a severe burn, immunodeficiency disorder, hematologic disorder, or metastatic malignancy.
  • Have had documented osteomyelitis on the target ulcer leg within 6 months preceding the screening visit.
  • Have severe edema of the target ulcer leg.
  • If being treated with Xenaderm, must stop treatment prior to enrolling in the study.
  • Have received treatment with glucocorticoids for > 10 consecutive days within 6 months prior to the start of the study.
  • Have received chemotherapy or radiation therapy within the past 5 years.
  • Therapy of the target ulcer with tissue-engineered cell-based skin equivalents within 30 days preceding the Screening Visit (e.g., Apligraf®).
  • Therapy of the target ulcer with topical growth factors within 1 week preceding the Screening Visit.
  • Current therapy with systemic or topical antibiotics or systemic therapy with cytotoxic drugs.

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

88 participants in 2 patient groups

HP828-101
Experimental group
Treatment:
Device: HP828-101
Standard of Care
Active Comparator group
Description:
For DFU SoC is a hydrogel. For PU SoC is a hydrocolloid gel.
Treatment:
Device: Hydrogel/Hydrocolloid

Trial contacts and locations

11

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems